The stock of Acelyrin Inc. (NASDAQ:SLRN) decreased by -$0.67 on Tuesday to finish at $10.21, down -6.16 percent. The last five days have seen an average of 3,666,620 shares of common stock traded. The average number of shares traded over the last 20 days was 2,217,085, while the average volume over the last 50 days totaled 1,282,176.
SLRN stock dropped -61.54% since last month. On 09/13/23, the company’s shares reached a one-month low of $9.76. The stock touched a high of $29.88, after rallying from a low of $9.76 in 52 weeks. The price of SLRN stock has declined by -56.55%. Still, the stock price is down -65.83% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
SLRN stock investors should be aware that Acelyrin Inc. (SLRN) stock had its last reported insider trading activity 134 days ago on May 09. On May 09, 10% Owner Westlake BioPartners Fund II, acquired 1,250,000 shares at $18.00 each. This transaction resulted in the insider spending $22,500,000. On May 09, SEIDENBERG BETH C added 1,250,000 shares at a price of US$18.00. After the transaction, the insider now owns 9,790,729 shares. Director SEIDENBERG BETH C had earlier bought 60,000 shares on May 09 for $18.00 a share. The transaction was completed for $1,080,000.
Financial Health
For the three months ended June 29, Acelyrin Inc.’s quick ratio was 25.30, while its current ratio was 25.30, indicating its ability to pay off its debt.
Earnings Surprise
According to Acelyrin Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Acelyrin Inc.’s quarterly earnings would be -$0.4, but it ended up being -$0.76, beating the consensus by 47.40%. At the end of Acelyrin Inc.’s most recent quarter ended June 29, its liabilities totaled 34.06 million, while its total debt was $1.36 million. Equity owned by shareholders amounts to $97.24 million.
Technical Picture
Here’s a quick look at Acelyrin Inc.’s (SLRN) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 17.23%, suggesting the stock is oversold, with a 379.95% historical volatility rate.
The stochastic %K and %D were 5.43% and 6.26% respectively, while the average true range (ATR) was 2.47. Based on the 14-day stochastic reading of 2.30%, the RSI (14) reading is 22.24%. On the 9-day MACD Oscillator, the stock is at -5.75, and the 14-day reading is at -9.14.
Analyst Ratings
Acelyrin Inc. (NASDAQ: SLRN) was downgraded by Morgan Stanley to a an Equal-weight rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Acelyrin Inc. (SLRN) an Buy rating. SLRN is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is SLRN’s price target for the next 12 months?
The current consensus forecast for the stock is between $19.00 and $68.00, with a median target price of $30.50. In analyzing these forecasts, the average price target given by analysts for Acelyrin Inc. (SLRN) is $37.00.
